mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
Abstract
Purpose: Triple-negative breast cancer (TNBC) is a highly heterogeneous disease and has the worst outcome among all subtypes of breast cancers. Although PARP inhibitors represent a promising treatment in TNBC with BRCA1/BRCA2 mutations, there is great interest in identifying drug combinations that can extend the use of PARP inhibitors to a majority of TNBC patients with wild-type BRCA1/BRCA2. Here we explored whether mTOR inhibitors, through modulating homologous recombination (HR) repair, would provide therapeutic benefit in combination with PARP inhibitors in preclinical models of BRCA-proficient TNBC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 31, 2016
- Source ID
- 10.1158/1078-0432.ccr-15-1772
Entities
People
- Curtis Chun-jen Lin
- Funda Meric-bernstam
- Gordon B. Mills
- Guang Peng
- Hui Dai
- Kaiyi Li
- Qingxin Liu
- Shiaw-Yih Lin
- Wei Mo
- Yang Peng
- Yulong Liang
Organizations
- Baylor College of Medicine
- United States Department of Defense
- University of Texas at Austin